You are here

Article Text

Article menu
Download PDFPDF
Epidemiology
The association of current hormonal contraceptive use with type-specific HPV detection
  1. Khalil G Ghanem1,
  2. S Deblina Datta2,
  3. Elizabeth R Unger2,
  4. Michael Hagensee3,
  5. Judith C Shlay4,
  6. Peter Kerndt5,
  7. Katherine Hsu6,
  8. Laura A Koutsky7
  1. 1Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  2. 2Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  3. 3Louisiana State University Health Science Center, New Orleans, Louisiana, USA
  4. 4Denver Public Health, Denver, USA
  5. 5Los Angeles County Department of Public Health, Los Angeles, California, USA
  6. 6Massachusetts Department of Public Health, Boston, USA
  7. 7Department of Epidemiology, University of Washington, Seattle, USA
  1. Correspondence to Khalil G Ghanem, JHUBMC, ID Division, 4940 Eastern Ave, B3N Suite 352, Baltimore, MD 21224, USA; kghanem{at}jhmi.edu

Abstract

Background Increased duration of hormonal contraceptive (HC) use may be positively associated with the risk of invasive cervical cancer.

Methods This is a secondary analysis from the HPV Sentinel Surveillance Study. The authors examined the association between type-specific human papillomavirus (HPV) detection and current HC use among 7718 women attending 26 sexually transmitted disease, family planning and primary care clinics in the USA.

Results There was an association between HC use and HPV-16 detection (adjusted prevalence rate ratio 1.34 (95% CI 1.05 to 1.71) for oral contraceptive users and 1.41 (1.01 to 2.04) for depot-medroxyprogesterone acetate users); there was no association between HC use and detection of other HPV types or any HPV overall.

Conclusions Longitudinal studies are needed to better define this type-specific association and its clinical significance.

  • Hormonal contraception
  • HPV
  • human papillomavirus
  • Papanicolaou smear
  • infectious disease
  • treponemal infection
  • Treponema pallidum
  • syphilis serology
  • law ethics
  • notification
  • chlamydia
  • epidemiology
  • cervical cancer
  • self-sampling
  • cervix
  • epidemiology
  • contraception

https://doi.org/10.1136/sextrans-2011-050005

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding All funding for the HPV Sentinel Surveillance Study was provided by the Centers for Disease Control and Prevention. Additional funding from the National Institutes of Health (K23HD047395) was provided to KGG.

    • Competing interests Honoraria: KGG (Merck). Portions of the data were presented (abstract #P2.54) at the 18th International Society for Sexually Transmitted Diseases Research conference in London, 28 June–1 July 2009.

    • Ethics approval IRBs of all participating institutions.

    • Provenance and peer review Not commissioned; externally peer reviewed